Elisa Garcia-Garayoa

Summary

Affiliation: Paul Scherrer Institute
Country: Switzerland

Publications

  1. ncbi New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors
    E Garcia Garayoa
    Paul Scherrer Institute, Center for Radiopharmaceutical Science, Villigen PSI, Switzerland
    Q J Nucl Med Mol Imaging 51:42-50. 2007
  2. ncbi Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors
    Elisa Garcia-Garayoa
    Center for Radiopharmaceutical Science, Paul Scherrer Institute, CH 5232 Villigen PSI, Switzerland
    Nucl Med Biol 33:495-503. 2006
  3. ncbi Chemical and biological characterization of new Re(CO)3/[99mTc](CO)3 bombesin analogues
    Elisa Garcia Garayoa
    Paul Scherrer Institute, Centre for Radiopharmaceutical Science, CH 5232 Villigen PSI, Switzerland
    Nucl Med Biol 34:17-28. 2007
  4. doi A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours
    Elisa Garcia-Garayoa
    Paul Scherrer Institute, Center for Radiopharmaceutical Science, CH 5232, Villigen PSI, Switzerland
    Eur J Nucl Med Mol Imaging 36:37-47. 2009
  5. doi Influence of the molecular charge on the biodistribution of bombesin analogues labeled with the [99mTc(CO)3]-core
    Elisa Garcia Garayoa
    Paul Scherrer Institute, Centre for Radiopharmaceutical Science, CH 5232 Villigen PSI, Switzerland
    Bioconjug Chem 19:2409-16. 2008
  6. ncbi Preclinical evaluation of a new, stabilized neurotensin(8--13) pseudopeptide radiolabeled with (99m)tc
    Elisa Garcia-Garayoa
    Center for Radiopharmaceutical Science, Paul Scherrer Institute, Villigen, Switzerland
    J Nucl Med 43:374-83. 2002
  7. ncbi In vitro and in vivo evaluation of a 99mTc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors
    Roberto La Bella
    Center for Radiopharmaceutical Science, Paul Scherrer Institute, CH 5232 Villigen, Switzerland
    Nucl Med Biol 29:553-60. 2002
  8. doi Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors
    Christian Schweinsberg
    Paul Scherrer Institute, Centre for Radiopharmaceutical Science, CH 5232 Villigen PSI, Switzerland
    Bioconjug Chem 19:2432-9. 2008
  9. ncbi Synthesis and in vitro characterization of organometallic rhenium and technetium glucose complexes against Glut 1 and hexokinase
    Roger Schibli
    Center for Radiopharmaceutical Science, ETH PSI USZ, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland
    Bioconjug Chem 16:105-12. 2005

Collaborators

Detail Information

Publications9

  1. ncbi New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors
    E Garcia Garayoa
    Paul Scherrer Institute, Center for Radiopharmaceutical Science, Villigen PSI, Switzerland
    Q J Nucl Med Mol Imaging 51:42-50. 2007
    ..Additionally, a spacer was inserted between the chelator and the binding sequence in order to further improve the in vivo uptake. The analogues were labeled with the [(99m)Tc(CO)(3)]-core and tested...
  2. ncbi Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors
    Elisa Garcia-Garayoa
    Center for Radiopharmaceutical Science, Paul Scherrer Institute, CH 5232 Villigen PSI, Switzerland
    Nucl Med Biol 33:495-503. 2006
    ..Modifications at the cleavage bonds 8-9 and 11-12 led to the synthesis of NT-XII, NT-XIII and NT-XVIII, three new stabilized analogues. (NalphaHis)Ac was coupled to the N-terminus for labeling with [(99m)Tc]-tricarbonyl...
  3. ncbi Chemical and biological characterization of new Re(CO)3/[99mTc](CO)3 bombesin analogues
    Elisa Garcia Garayoa
    Paul Scherrer Institute, Centre for Radiopharmaceutical Science, CH 5232 Villigen PSI, Switzerland
    Nucl Med Biol 34:17-28. 2007
    ....
  4. doi A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours
    Elisa Garcia-Garayoa
    Paul Scherrer Institute, Center for Radiopharmaceutical Science, CH 5232, Villigen PSI, Switzerland
    Eur J Nucl Med Mol Imaging 36:37-47. 2009
    ..A new analogue based on NT(8-13), NT-XIX, with the three enzymatic cleavage sites stabilised, was synthesised and tested...
  5. doi Influence of the molecular charge on the biodistribution of bombesin analogues labeled with the [99mTc(CO)3]-core
    Elisa Garcia Garayoa
    Paul Scherrer Institute, Centre for Radiopharmaceutical Science, CH 5232 Villigen PSI, Switzerland
    Bioconjug Chem 19:2409-16. 2008
    ..The introduction of a single negative charge may be useful in the development of new BBS analogues to obtain an improved biodistribution profile, with increased tumor uptake and better imaging...
  6. ncbi Preclinical evaluation of a new, stabilized neurotensin(8--13) pseudopeptide radiolabeled with (99m)tc
    Elisa Garcia-Garayoa
    Center for Radiopharmaceutical Science, Paul Scherrer Institute, Villigen, Switzerland
    J Nucl Med 43:374-83. 2002
    ..Finally, (NalphaHis)Ac was coupled to the N-terminus for (99m)Tc(CO)(3) labeling. This peptide was characterized both in vitro and in vivo...
  7. ncbi In vitro and in vivo evaluation of a 99mTc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors
    Roberto La Bella
    Center for Radiopharmaceutical Science, Paul Scherrer Institute, CH 5232 Villigen, Switzerland
    Nucl Med Biol 29:553-60. 2002
    ..We therefore conclude that [99mTc(I)-PADA-AVA]bombesin (7-14) might have promising characteristics for applications in nuclear medicine, namely for diagnosis of GRP receptor overexpressing tumors...
  8. doi Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors
    Christian Schweinsberg
    Paul Scherrer Institute, Centre for Radiopharmaceutical Science, CH 5232 Villigen PSI, Switzerland
    Bioconjug Chem 19:2432-9. 2008
    ..In conclusion, the introduction of a carbohydrated linker substantially improved the biodistribution properties of BBS analogues labeled with the 99mTc-tricarbonyl core...
  9. ncbi Synthesis and in vitro characterization of organometallic rhenium and technetium glucose complexes against Glut 1 and hexokinase
    Roger Schibli
    Center for Radiopharmaceutical Science, ETH PSI USZ, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland
    Bioconjug Chem 16:105-12. 2005
    ..The current results seem to preclude the use of these compounds as [18F]-FDG surrogates primarily due to the low cellular uptake via Glut1...